drugset / Trial / NCT01614912

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

NCT01614912

Phase 3 Completed 284 enrolled Sumitomo Pharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

Timeline

Start
2012-08
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg Oral
Subject Lurasidone Small molecule 80 mg Oral

Indications